STANS, Switzerland, April 21, 2017 /PRNewswire/ -- (Booth #15) – NLS Pharma (NLS), a Swiss-based biotech group founded to develop first-in-class treatments for attention deficit hyperactivity disorder (ADHD) and other neurological disorders, today announced the following two presentations during the 6th Annual World Congress on ADHD being held in Vancouver, Canada, April 20-23, 2017:
|
Poster Presentation | |
|
Abstract: |
Poster presentation—P-09-003 |
|
Location: |
Exhibition Hall A, Vancouver Convention Center |
|
Title: |
"Periodic limb movements, onset latency and ferritin levels in children with ADHD" |
|
Presenter: |
Dr. Michel Lecendreux, APHP Robert Debre Hospital, Paris |
|
Date: |
Friday, April 21, 2017, 2:30 pm (PT) |
|
Free Communication Session | |
|
Abstract: |
Free communication abstract—FC-01 |
|
Location: |
East Meeting Room 13, Vancouver Convention Center |
|
Title: |
"Excessive daytime sleepiness in attention-deficit/hyperactivity disorder vs. narcolepsy: subjective and objective measures in adults" |
|
Presenter: |
Dr. Michel Lecendreux, APHP Robert Debre Hospital, Paris |
|
Date: |
Friday, April 21, 2017, 4:00 pm (PT) |
"NLS Pharma is grateful to Dr. Lecendreux and his colleagues for presenting this research to the World Congress on ADHD," said Alex Zwyer, CEO at NLS Pharma Group. "Dr. Lecendreux's presentations at this preeminent global forum further illuminate the strong link between sleep quality, awakeness and ADHD. This link is the hypothesis underpinning our lead ADHD pipeline candidate, NLS-1 (mazindol) in Adults with DSM-5 ADHD, for which results from our just-completed Phase 2 clinical trial will be announced on May 30."
For more information on NLS Pharma, please visit booth #15 at the World Congress or visit http://nlspharma.com/
About ADHD
A major unmet medical need remains in the treatment of attention deficit hyperactivity disorder (ADHD). In recent studies the prevalence of ADHD is estimated to be 7 to 8% of school-age children and 4 to 5% of adults. In the US, pharmacological approaches to treatment are the most common, and typically consist of stimulant medication, such as methylphenidate, dexmethylphenidate, mixed amphetamine salts and lisdexamfetamine dimesylate. While stimulant medication is an effective treatment for many of the symptoms associated with ADHD, there are concerns about diversion of these medications for misuse and abuse, and some rare but serious cardiovascular side-effects can occur with the use of stimulant medication. Non-stimulants such as atomoxetine, clonidine and guanfacine have also been found to be efficacious in treating ADHD, but the efficacy of these agents may not be comparable to that seen with stimulants. Even with stimulant treatment, optimal functioning occurs in only roughly one in four children with ADHD. Despite considerable advances in our understanding and treatment of ADHD, the disorder remains difficult to manage and further treatment options need to be developed.
About NLS Pharma
NLS Pharma (NLS) is a privately owned, Swiss-based biotech group focusing on compounds to treat ADHD, sleep disorders and cognitive impairment. Our aim is to create new approaches to treat mental and behavioral disorders and enhance cognitive function in healthy people. NLS Pharma is a privately-owned enterprise managed by a top level team of experts who have demonstrated their value and experience with large pharmaceutical companies, and work closely with ADHD and sleep-related disorders key opinion leaders.
NLS Pharma Contacts:
Media
Jon Siegal, MSLGROUP
Danae McKenzie, MSLGROUP
781-684-0770
nlspharma@mslgroup.com
Analysts/Business Development
Hervé Girsault, Head of M&A and Business Development
NLS Pharma
hg@nls-pharma.com
SOURCE NLS Pharma